GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » EPS without NRI

Urologix (Urologix) EPS without NRI : $-0.09 (TTM As of Mar. 2015)


View and export this data going back to 1996. Start your Free Trial

What is Urologix EPS without NRI?

Urologix's earnings per share without non-recurring items for the three months ended in Mar. 2015 was $-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2015 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Urologix's EPS without NRI or its related term are showing as below:

ULGX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Urologix's EPS (Diluted) for the three months ended in Mar. 2015 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2015 was $-0.23.

Urologix's EPS (Basic) for the three months ended in Mar. 2015 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2015 was $-0.23.


Urologix EPS without NRI Historical Data

The historical data trend for Urologix's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix EPS without NRI Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.26 -0.32 -0.25 -0.22

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.03 -0.02 -0.02 -0.02

Competitive Comparison of Urologix's EPS without NRI

For the Medical Devices subindustry, Urologix's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Urologix's PE Ratio without NRI falls into.



Urologix EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Urologix  (OTCPK:ULGX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Urologix EPS without NRI Related Terms

Thank you for viewing the detailed overview of Urologix's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009